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Abstract
We investigated blocking the TGF-b signaling pathway in HCC using two small molecule inhibitors (LY2157299, LY2109761)
and a neutralizing humanized antibody (D10) against TGF-bRII. LY2157299 and LY2109761 inhibited HCC cell migration on
Laminin-5, Fibronectin, Vitronectin, Fibrinogen and Collagen-I and de novo phosphorylation of pSMAD2. LY2157299
inhibited HCC migration and cell growth independently of the expression levels of TGF-bRII. In contrast to LY2157299, D10
showed a reduction in pSMAD2 only after a short exposure. This study supports the use of LY2157299 in clinical trials, and
presents new insights into TGF-b receptor cycling in cancer cells.
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Introduction
Hepatocellular carcinoma (HCC) is a lethal cancer, being the
third cause of cancer-related death [1]. As a result of improved
early detection and screening, the overall survival for this cancer
has modestly improved. Nevertheless, the prognosis of patients
with advanced disease remains unsatisfactory [2]. Sorafenib is the
only approved agent to improve the overall survival of patients
with advanced disease [3]. However, the associated side effects of
sorafenib, and the rapid progression of disease despite sorafenib
treatment, highlight the need for new, additional treatments [4].
Transforming growth factor-beta (TGF-b) signaling occurs
following the binding of the TGF-b ligand to TGF-b receptor
(R)I that heterodimerizes with the TGF-b RII. This heterodimer
complex phosphorylates the intracellular protein Smad-2 and 3,
activating a downstream cascade that produces a nuclear
transduction protein [5].
TGF-b is an important pathophysiological pathway in the liver
associated with fibrogenesis, and promoting extracellular matrix
deposition in hepatic stellate cells after viral or metabolic injury.
The final outcome of this process is a decreased liver function,
which often presents clinically as liver cirrhosis. This loss of liver
function commonly precedes the onset of Hepatocellular Carci-
noma (HCC) in Western countries [6,7]. One of the ligands of the
TGF-b signaling cascade, TGF-b1, is often detected in blood and
urine of patients with HCC and its presence is associated with
poor prognosis [8–10]. Thus, targeting TGF-b signaling in HCC
has been proposed as a novel approach to delay the progression of
HCC, and to target the underlying disease which predisposes to
HCC [10].
However, a reduced expression of TGF-bRII on the HCC cell
surface has been described to be associated with a more aggressive
phenotype, while there is still a poor understanding of the role of
TGF-b signaling in such a context [11]. Recently, the TGF-bRI
kinase inhibitor LY2109761 was found to up-regulate the
expression of E-cadherin in HCC cell migration/invasion and
the epithelial mesenchymal transition (EMT) in vitro and in vivo
models [12]. Furthermore, LY2109761 also blocked the invasion
of HCC cells into blood vessels via dephosphorylation of the
intracellular tail of b1-integrin at the T788-789 residue [13].
Because the invasion of HCC blood vessels is an important
negative prognostic factor, this observation justifies the blocking of
TGF-b signaling in HCC [14–16]. In fact, LY2109761 demon-
strated a stronger anti-angiogenic effect than bevacizumab,
resulting in inhibition of tumoral growth [17]. TGF-b signaling
also regulates the expression of connective tissue growth factor
(CTGF), which is associated with a desmoplastic reaction of the
tumor and/or the surrounding tissue microenvironment [18,19].
In such conditions, LY2109761 inhibits CTGF production,
reducing the stromal component of the tumor and slowing the
HCC growth in vivo [20]. Based on these observations, a phase II
clinical trial was initiated in patients with HCC using LY2157299,
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a second small molecule inhibitor of the TGF-b receptor Type I
kinase.
Aim of this study is to characterize two small molecule inhibitors
of TGF-b receptor Type I kinase (TGF-bRI) and to compare their
activity to a specific TGF-b receptor Type II inhibitor, the
monoclonal antibody D10 [21]. Such a strategy of comparing
specific inhibitors in HCC has not been previously investigated
and may help to better understand the relevance of this pathway in
HCC patients. Finally, it may also provide some insight into future
use of such inhibitors in HCC.
Figure 1. Comparison of the effect of two TGF-bR inhibitor analogs, LY2109761 and LY2157299, on HCC cell migration on different
extracellular matrix components. (A) HLE and (B) HLF cells were allowed to migrate for 16 hours on fibronectin (Fn), vitronectin (Vn), laminin-5
(Ln-5) and fibrinogen (Fg) in the presence or absence (vehicle) of increasing concentrations of LY2109761 or LY2157299. All conditions were
performed in duplicate, and each experiment was repeated at least three times. Results of representative experiments are shown, and values are
expressed as mean 6 standard deviation.
doi:10.1371/journal.pone.0067109.g001
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Materials and Methods
Cell Culture and Reagents
HepG2 and HLE human cell lines were obtained from the
European Collection of Cell Cultures (ECACC). This cell bank
performed cell line certification and cells were propagated in the
laboratory for fewer passages before the experiments. Cell cultures
were grown in DMEM High Glucose (4,5 g/l) supplemented with
L-Glutamine and 10% fetal bovine serum in a humidified
atmosphere of 37uC, 5% CO2. LY2157299 was kindly provided
by Lilly (Indianapolis, IN, USA) and D10, a fully human
monoclonal antibody directed against the TGF-b receptor II,
was obtained from ImClone Systems (New York, NY, USA).
Human recombinant TGF-b1 was purchased from Peprotech
(Rocky Hill, NJ, USA). Rabbit polyclonal anti-Phospho-SMAD2,
rabbit polyclonal anti-total SMAD2, mouse monoclonal anti-
Phospho p44/42, rabbit polyclonal anti p44/p42, rabbit poly-
clonal anti-Phospho-Akt, and rabbit polyclonal anti-total Akt
antibodies were purchased from Cell Signalling technology, Inc.
(Beverly, MA, USA). Mouse monoclonal anti-human FAK
(pY397) antibody was purchased from BD Transduction Labora-
tories (Franklin Lakes, NJ USA). Fluorescein isothiocyanate
labeled phalloidin was purchased from Sigma Aldrich (St. Louis,
MO, USA). Monoclonal antibody directed against human E-
Cadherin was obtained from Alexis Biochemicals (San Diego, CA,
USA). A polyclonal antibody against p-Smad2 was purchased
from Cell Signaling (Denvers, MA). An anti-isotype IgG human
was purchased from GenTex (Irvine, CA).
Analysis of Gene Expression
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,)
and underwent DNAse treatment (TURBO DNA-freeTM Am-
bionH). Reverse Transcription (RT) was then carried out with
random primers using 1 mg of total RNA from each sample.
Quantitative RT-PCR was performed using pre-designed primers
and SYBR GreenH master mix (Biorad). Housekeeping Glyceral-
dehyde 3-phosphate dehydrogenase gene (GAPDH) was used as
endogenous control. The following primers were obtained from
Integrated DNA TechnologiesH (Leuven, Belgium): TGFB1:
Forward: 59- CCG AGA AGC GGT ACC TGA AC-39. Reverse:
59- GAG GTA TCG CCA GGA ATT GTT G-39. TGFBR2:
Forward: 59- GCT GAT CAC CGC CTT CCA -39. Reverse: 59-
CAG GTC CTC CCA GCT GAT GA-39 VEGF-A: Forward: 59-
CAG ATG TCC CGG CGA AGA -39. Reverse: 59- GAG GGC
GAG TCC CAG GAA-39. CTGF: Forward: 59- GCA TCC GTA
CTC CCA AAA TCT C-39. Reverse: 59-GGC AGG GTG GTG
GTT CTG T39. MMP-2: Forward: 59- TGA CCC CAC TGC
GGT TTT -39. Reverse: 59- GCG GCC AAA GTT GAT CAT G
-39. GAPDH: Forward: 59- CCA CAT CGC TCA GAC ACC
AT-39. Reverse: 59- GCG CCC AAT ACG ACC AAA T -39.
Cell Transfection
HLE and HepG2 cells were transfected with siRNAs targeting
the SMAD2, SMAD3 gene or a nonsilencing control (Integrated
DNA Technologies) using TransIT-TKO (Mirus, U.S.A.). Eight
hours after transfection, cells were serum starved and stimulated
with 5 ng/ml of TGF-b1. After forty-eight hours, cells were
trypsinized, counted and allowed to migrate on collagen I or
Matrigel.
Cell Migration Assay
Trans-wells migration assays were performed as previously
reported [12]. Briefly, trans-well membranes (Corning, U.S.A.)
were pre-coated with 10 mg/ml of Collagen I or Matrigel.
SMAD2- silenced cells or cells treated with LY2109761,
LY2157299 (10 mM) or D10 (25 mg/ml) were incubated in the
presence or absence of TGF-b1 (5 ng/ml) for 48 hours before
being trypsinized and loaded on the top chamber of the trans-well
plates, and allowed to migrate for 16 hours in the presence or
absence of a new addition of LY2109761, LY2157299, D10 or
TGF-b1. After fixation with 4% paraformaldehyde, migrated cells
were stained with crystal violet and quantified.
Proliferation and Apoptosis Assays
Proliferation assays were performed as previously described
[22]. Briefly, 16104 cells were plated onto 24-well plates. Every
two days LY2109761, LY2157299 (10 mM) or D10 (25 mg/ml)
were added. Cells were fixed with 4% paraformaldehyde, stained
with crystal violet and absorbance was quantified with a
spectrophotometer. For apoptosis, cells were treated with
LY2109761, LY2157299 (10 mM) or D10 (25 mg/ml) for 48 hours
and the TUNEL Detection kit was used according to the
manufacturer’s instructions (TUNEL Detection kit Genscript,
Piscataway, NJ).
Western Blot Analysis
Total proteins were extracted using a lysis buffer containing
30 mmol/L Tris-HCl (pH 7.5), 5 mmol/L EDTA, 150 mmol/L
NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS,
and 10% glycerol on ice for 30 min. Lysates were then centrifuged
at 13,000 rpm for 10 min at 4uC and supernatants were collected.
Proteins were quantified by the Bradford protein assay (Biorad),
Figure 2. Effect of LY2109761 and LY2157299 on SMAD2
phosphorylation upon TGF-b1. (A) Two different HCC cell lines HLE
and HLF were pretreated for 16 hours with 100 nM of LY2109761 or
LY2157299 and then stimulated with 2 ng of TGF-b1 for 30 min.
Phosphorylation of SMAD2 was detected in immunoblots using a rabbit
polyclonal antibody directed against Phospho-Smad2 (Ser465/467). (B)
Effect of LY2109761 and LY2157299 on E-cadherin expression in HLE
and HLF. Increasing expression of E-cadherin is observed in HLE and
HLF cells after treatment with both inhibitors for 48 hours.
doi:10.1371/journal.pone.0067109.g002
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Figure 3. RNA expression levels of TGF-b receptor I, TGF-b receptor II and TGF-b1 in different HCC cell lines evaluated by real-time
PCR. Values are expressed as relative gene expression versus GAPDH and represent the mean 6SD of three independent experiments.
doi:10.1371/journal.pone.0067109.g003
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separated in 10% SDS-PAGE and transferred to PVDF mem-
branes. After blocking with 5% w/v nonfat dry milk 1X TBS,
0.1% Tween-20, the membranes were incubated overnight at 4uC
with the primary antibody, washed and then incubated with a
horse peroxidase-conjugated secondary antibody. The protein
bands were visualized using the ECL protein detection (Amer-
sham).
Ethic Statement
Approval for the study was obtained from the local Ethics
Committee of the Azienda Ospedaliero-Universitaria Policlinico,
Bari (Apulia) Italy, and patients gave prior written informed
consent to the use of their tissues. This study was performed in
accordance with the Helsinki Declaration and informed written
consent was obtained from all patients. Finally, the data were
analyzed anonymously.
HCC Patients and Tissue Preparations
30 HCC patients, of ages ranging from 59 to 76 years, 12
females and 18 males, were studied. In 26 patients the etiology was
viral (15 patients with hepatitis C and 11 patients with hepatitis B),
and in four patients alcoholic. Surgical samples were obtained.
Tissues were cut in two pieces; one was processed for routine
histology, and the other was immediately snap-frozen in liquid
nitrogen. Approval for the study was obtained from the local
Ethics Committee, and patients gave prior written informed
consent to the use of their tissues.
Immunofluorescence
Expression of type II TGF-b receptor was detected in HCC
tissues using the fully human monoclonal antibody D10 (Imclone).
Briefly, the frozen tissue sections (8-mm thick) were fixed with PBS
containing 4% Paraformaldehyde. Tissues were then stained with
primary antibody at 37uC for 30 min., washed 3 times with PBS
and incubated with an Alexa FluorH 594 secondary antibody
(Molecular Probes). Tissues were washed 5 times with PBS and
mounted with mounting media containing DAPI (VectashieldH).
Alpha smooth muscle actin was detected using the monoclonal
antibody clone 1A4 (DAKO). For cell cultures, HepG2 and HLE
cells were seeded onto glass coverslips at 36104 in 24-well plates
overnight and treated with LY2157299 or D10 in serum-free
medium. Cells were then stimulated with TGF-b1 in the presence
or absence of LY2157299 or D10. LY2157299, D10 or TGF-b1
were added daily and after 72 hours cells were fixed with 4%
Figure 4. Comparison of the effect between LY2157299 and the fully humanized monoclonal antibody D10 in HCC cell migration.
LY2157299 and D10 were tested in two different HCC cell lines, (A) HepG2 and (B) HLE, that were allowed to migrate on collagen I or matrigel.
LY2157299, but not D10, was able to inhibit cell migration of both cell lines on both extracellular matrix components. An anti-isotype IgG was used as
internal negative control. Results of representative experiments are shown, and values are expressed as mean 6 standard deviation. *P,0.05
**P,0.001 versus TGF-b1.
doi:10.1371/journal.pone.0067109.g004
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Figure 5. Comparison of the effect between LY2157299 and the fully humanized monoclonal antibody D10 on HCC cell
morphology, actin cytoskeleton and E-cadherin expression. HepG2 cells were seeded onto glass coverslips at 3 x104 cells/ml in 24-well plates
overnight and treated with control (A, G) or LY2157299 (E, K) or D10 (C, I) alone in serum-free medium. Then, cells were stimulated with TGF-b1 in the
absence (B, H) or presence of LY2157299 (F, L) or D10 (D, J). LY2157299, D10 or TGF-b1 were added daily and after 72 hours cells were live-imaged
under a phase contrast microscope. For immunofluorescence, cells were fixed with 4% paraformaldehyde, stained with TRITC-phalloidin and anti-E-
cadherin antibody and examined under a NIKON eclipse E1000 fluorescence microscope. (M) Cell area was quantified using a combination of two
digital image analysis softwares (ImageJ and Adobe Photoshop) and results were plotted as cell area (mm2) per random field.**P,0.01.
doi:10.1371/journal.pone.0067109.g005
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paraformaldehyde in PBS for 10 minutes at room temperature
(R.T.) and live-imaged under a phase contrast microscope
(Olympus). For immunofluorescence, cells were fixed, washed
with PBS, permeabilized with 0.2% Triton X-100 and stained
with both TRITC-phalloidin and anti-E-cadherin antibody (BD
Figure 6. Effect of LY2157299 and D10 on SMAD2 activity in HCC cells. (A) HepG2 and HLE cells were preincubated with LY2157299 (10 mM)
or D10 (25 ng/mL) and then stimulated with TGF-b1 (5 ng/mL) in the presence or absence of LY2157299 or D10 for 30 min or 24 hours. Proteins were
extracted and western blotting analysis was performed. Phosphorylation of SMAD2 was detected using a rabbit polyclonal antibody directed against
phospho-Smad2 (Ser465/467). (B) HepG2 and HLE cells were silenced for SMAD2, or non-silencing control and cell migration assay was performed.
Migrated cells were indicated as migratory index versus non TGF-b1-stimulated control. ***P,0.001 versus TGF-b1-stimulated control-siRNA.
doi:10.1371/journal.pone.0067109.g006
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Figure 7. Immunofluorescence staining of F-actin and p-FAK in HepG2 and HLE siRNA for Smad-2 and Smad-3 after stimulation
with TGF-b. HepG2 and HLE cells silenced for Smad-2 and Smad-3 were incubated with TGF-b under the same experimental conditions described
for migration experiments. Cells were fixed with 4% paraformaldehyde, stained with TRITC-phalloidin and anti-pFAK antibody and examined under a
NIKON eclipse E1000 fluorescence microscope. Mag=6006.
doi:10.1371/journal.pone.0067109.g007
Targetting TGF-b Pathway in HCC
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Transduction LaboratoriesTM). Stained cells were examined under
a NIKON eclipse E1000 fluorescence microscope.
Statistical Analysis
Statistical analyses of the migration, invasion and mRNA were
performed using two-tailed Student t test or ANOVA (analysis of
variance) and statistical significance was set at a P value of ,0.05.
Figure 8. Effect of LY2157299 and D10 on CTGF and VEGF gene expression in HCC cell lines. (A) HepG2 and (B) HLE cells were
preincubated with LY2157299 (10 mM) or D10 (25 ng/mL) and then stimulated with TGF-b1 (5 ng/mL) in the presence or absence of LY2157299 or
D10. After 48 hours, RNA was extracted and real-time PCR was performed. Values are expressed as relative gene expression versus GAPDH and
represent the mean 6SD of three independent experiments. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0067109.g008
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All experimental data are described as the mean 6SD. Qualitative
variables are summarized as counts and percentages. Associations
between variables were assessed using the chi-square test or two-
sided Fisher’s exact test as appropriate. Results were considered
statistically significant at p-values ,0.05. Analyses were performed
with SAS 9.3 software for Windows OS personal computer.
Figure 9. Immunofluorescence staining of TGF-b receptor II in frozen HCC tissues. Tissues from 30 patients with HCC were stained using
D10, a fully humanized monoclonal antibody directed against TGF-b receptor II (red) and alpha smooth muscle actin with the monoclonal antibody
clone 1A4 (green). In 11 out of 30 HCC tissues (36.6%) positivity for TGF-b receptor II was obtained; representative cases of TGF-b receptor II-positive
(patient #22 and #29) or -negative (patients #8 and #19) tissues are shown.
doi:10.1371/journal.pone.0067109.g009
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Figure 10. Immunofluorescence staining of p-Smad2 in frozen HCC tissues. Tissues from 30 patients with HCC were stained using an anti-p-
Smad2 polyclonal antibody (red) and alpha smooth muscle actin with the monoclonal antibody clone 1A4 (green). In 20 out of 30 HCC tissues
(69.0%) positivity for p-Smad2 was obtained; representative cases of p-Smad2-positive (patient#1 and#3) or -negative (patients#7 and#9) tissues
are shown.
doi:10.1371/journal.pone.0067109.g010
Targetting TGF-b Pathway in HCC
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Results
After having observed that LY2109761 had an effect of
reducing HCC tumor progression [10], we tested LY2157299, a
novel and second TGF-bRI kinase inhibitor. LY2157299 is a
structural analog of LY2109761 with increased water solubility.
Firstly, we allowed HLE and HLF cells to migrate on different
extracellular matrix (ECM) components such as Fn, Vn, Ln-5 and
Fg, in the presence of LY2109761 or LY2157299 at increasing
concentrations. All the experimental conditions were identical for
treatments with both compounds. Like LY2109761, LY2157299
significantly inhibited (p,0.001) HLE and HLF migration on
different ECM substrates (Fig. 1) [12]. We found that the HCC
migration inhibiting effect was dose-dependent for both drugs. In
addition, LY2157299 and LY2109761 inhibited de novo phos-
phorylation of p-SMAD2 at the same efficiency in HLE and HLF
after stimulation with TGF-b1 (Fig. 2A). Further, both
LY2157299 and LY2109761 increased the expression of E-
cadherin in both HCC cell lines in a dose-dependent manner
(Fig. 2B). Taken together, these data demonstrate that both
LY2157299 and LY2109761 have similar functional and bio-
chemical effects. Because of its improved solubility, LY2157299
may be a more suitable candidate for TGF-b inhibition in vivo,
including use in clinical trials in humans.
We next compared the TGF-bRI inhibitor LY2157299 to D10,
a monoclonal antibody directed against TGF-bRII. Firstly, we
screened five different HCC cell lines for the expression of TGF-
bRI, TGF-bRII and TGF-b1 mRNA levels, to define the most
appropriate experimental model. HepG2 cells expressed the
highest levels of TGF-b receptors, TGF-bRI and TGF-bRII, as
well as TGF-b1, as compared to the other cell lines, Fig. 3.
To evaluate the drug effectiveness of LY2157299 and D10, we
selected two different HCC cell lines, HepG2 with the highest and
HLE with the lowest expression of TGF-bRI and TGF-bRII.
HepG2 cells have a constitutively low migratory activity on Coll I
and Matrigel. Addition of TGF-b1 significantly increases migra-
tion of these cells on Coll I and Matrigel (p,0.001). Surprisingly,
treatment with D10 did not antagonize the effect of TGF-b1 on
HepG2 migration, whereas LY2157299 efficiently inhibited this
effect (p,0.001). HLE cells have a constitutively highly migratory
activity on Coll I and Matrigel and are not responsive to the effect
of exogenous TGF-b1. However, as in HepG2, we found that
Table 1. Demographic charactersitics of patients.
Patient number TGF-b RII p-SMAD 2 Sex Age (yrs) Etiology Child-Pugh BCLC
1 pos pos M 77 HBV B A
2 pos pos F 69 HCV A A
3 pos pos M 80 HCV - HBV A B
4 neg pos M 66 HCV A B
5 neg neg M 58 HBV A B
6 pos pos M 69 HCV A B
7 pos pos F 71 HCV A B
8 neg pos M 72 Alcol A A
9 neg neg M 49 HCV A B
19 pos pos M 53 HCV A B
11 neg pos F 68 HCV+HBV B B
12 neg pos M 60 HCV A A
13 neg neg M 69 HBV B A
14 neg pos M 41 HBV B B
15 neg neg F 67 HCV A A
16 neg pos F 71 HCV A B
17 neg neg M 65 HCV B A
18 pos pos M 72 Unknown B A
19 neg neg M 66 HCV A A
20 pos pos M 63 HCV A A
21 neg pos M 73 HBV A B
22 neg pos M 56 HCV+Alcool A B
23 neg pos M 63 HCV A C
24 pos neg M 72 HCV B B
25 neg pos M 73 Alcool A B
26 neg neg M 59 Unknown A A
27 pos pos M 73 HCV A B
28 pos pos F 67 HCV B A
29 neg neg M 70 HCV A A
30 neg neg M 71 HCV A A
doi:10.1371/journal.pone.0067109.t001
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LY2157299 efficiently (p,0.001) inhibited migration of HLE,
whereas D10 did not. Despite the fact that addition of exogenous
TGF-b1 did not increase HLE motility, LY2157299 was still able
to inhibit cell migration in this cell line, Fig. 4. Together, these
data indicate that LY2157299 is more efficient than D10 in
inhibiting cell migration in HCC. On the contrary LY2109761,
LY2157299 and D10 did not display any effect on cell
proliferation and apoptosis, Fig. S1A–B.
In vitro, HepG2 cells grow in a pile-up anchorage-dependent
manner, leading to the formation of three-dimensional nodule-like
structures resembling the appearance of cancerous nodules in
patients with HCC. In the presence of exogenously added TGF-
b1, the architectural structure of these nodule-like masses is
remarkably rearranged. HepG2 cells grow in a flat-down manner,
and the nodule-like structures become larger. This effect is not
reversed by the presence of D10, whereas LY2157299 is able to
completely reverse the effect of TGF-b1. As a consequence,
HepG2 cells appear similar to their untreated rounded, nodule-
like cellular morphology (Fig. 5A–F and Fig. 5M). In the same
experimental conditions, HepG2 cells were stained for actin and
E-cadherin. In control conditions, E-cadherin is mainly localized
on the cellular surface at cell-cell contacts, mainly co-localized
with the cortical actin. In the presence of TGF-b1, E-cadherin was
no longer detected and actin was localized both at the cell surface
and in the cytosol. Addition of D10 to exogenous TGF-b1 did not
exert any effect and the cells appeared just like cells treated with
TGF-b1 alone. In contrast to D10 treatment, LY2157299
efficiently blocked the effect of exogenous TGF-b1 and E-cadherin
was co-localized with cortical actin similarly to controls, Fig. 5G–
L.
To better understand why D10 did not have similar effects to
the small molecule inhibitors, we investigated pSMAD2 expression
after the activation of TGF-bR signaling. After short-term
incubation (30 min), exogenous TGF-b1 phosphorylates SMAD2
in both HepG2 and HLE cells. This effect was inhibited by the
presence of D10 and LY2157299. However, after long-term
incubation (24 hours) with TGF-b1, phosphorylation of SMAD2
was detectable in the presence of D10 treatment, while cells
treated with LY2157299 had no pSMAD2 expression (Fig. 6B).
To demonstrate the role of pSMAD2 in TGF-b1 triggered
motility, we silenced SMAD2 in HLE and HepG2 cells, Fig. 6A.
Then, we challenged them to migrate on Coll I and Matrigel in
the absence or presence of exogenous added TGF-b1. After
SMAD2 knock-down in HLE and HepG2, TGF-b1 did not
increase migration on both substrates as compared to scrambled
controls, Fig. 6B. In the same experimental settings, SMAD3
knock-down did not affect HLE and HepG2 TGF-b1-dependent
migration, Fig. S2. To further explore the role of pSmad-2, we
investigated F-actin and pFAK distribution in silenced Smad-2
and Smad-3 HepG2 and HLE cells after stimulation with TGF-b
under the same experimental conditions used for migration
experiments.
In control siRNA HepG2 and HLE cells, F-actin was
distributed mainly cortically along the plasma membrane, while
pFAK was scattered throughout the cells. TGF-b treatment
altered the cellular ultrastructure, strongly increasing the cytoskel-
etal stress fibers distributed in the cells, and pFAK formation,
clustered at the ends of the stress fibers. The TGF-b mediated
effect was completely inhibited by Smad-2 but not by Smad-3
silencing Fig. 7.
These results suggest that pSMAD2 but not pSMAD3 plays a
pivotal role in regulating TGF-b1-dependent migration. Further-
more, HCC cells showed up-regulation of MMP-2 mRNA upon
TGF-b1 treatment, but knock-down for SMAD2 abolished MMP-
2 response, suggesting that MMP-2 is a down stream effector of
SMAD2, Fig. S3. Therefore, it is likely that the limited efficacy of
D10 as compared to LY2157299 is due to a short-time inhibition
of pSMAD2. In addition to these observations, we also compared
the effect of LY2157299 and D10 on CTGF and VEGF gene
expression of HLE and HepG2 cells. HLE and HepG2 cells
treated with TGF-b1 up-regulated CTGF and VEGF mRNA.
This effect was blocked by LY2157299, but not by D10 (Fig. 8).
Finally, we investigated the expression of TGF-bRII and p-
Smad2 in thirty patients with HCC by immunofluorescence
microscopy. To differentiate stromal from cancer cells, we
performed double staining with an anti a-SMA antibody, a
known marker of myofibroblasts. TGF-bRII was detected with a
spotty pattern in the section. It was mainly expressed on the
cellular membrane of cancer cells, although it was also occasion-
ally present on myofibroblasts surrounding the tumor, Fig. 9.
The staining of p-Smad2 presented a leopard-skin pattern, with
strongly positive clusters of cells and other areas with a weak or
absent staining. P-Smad2 was detected intracellularly, and limited
to cancer cells only, since no co-staining was observed in
myofibroblasts for a-SMA and p-Smad2, Fig. 10.
The percentage of patients positive to TGF-bRII was 45.0% (9/
20) in HCV positive and 22.2% (2/9) in patients with other
etiology; this difference was not statistically significant (Fisher’s
exact test: p = 0.412). The percentage of patients positive to TGF-
bRII classified as stage A in BCLC was 38.5% (5/13) as compared
to 40% in stage B (6/15), again not statistically significant (Fisher’s
Exact test: p = 1). There was no statistically significant difference
(Fisher’s exact test: p = 1) in the percentage of patients positive to
p-Smad2 when comparing HCV positive patients, 70% (14/20)
being p-Smad2 positive, with patients having other disease
etiology, of which 66.7% (6/9) were pSmad2 positive. The same
applied when comparing p-Smad2 among BCLC stages, except C
that could not be analysed: 53.8% (7/13) were positive in group A
vs 80% (12/15) in group B (Fisher’s exact test: p = 0.227).
The association between TGF-bRII and p-Smad2 resulted
barely statistically significant (p = 0.0459): only 1 among the 9 p-
Smad2 negative patients resulted positive to TGF-bRII and 10
among the 20 p-Smad2 positive resulted positive to TGF-bRII.
Stratified analysis, taking into account the BCLC classification was
performed only for stages A and B because only 1 patient resulted
BCLC stage C. The association between TGF-bRII and p-Smad2
in BCLC stage A resulted statistically significant (Fisher’s exact
test: p = 0.02): among 7 patients positive to p-Smad2, 5 resulted
positive to TGF-bRII and among the 6 p-Smad2 negative patients
none resulted positive to TGF-bRII. The association between the
two biomarkers in BCLC stage B was not statistically significant
(Fisher’s exact test: p = 1): among 3 p-Smad2 negative patients
only 1 was positive to TGF-b and among 12 p-Smad2 positive
patients, 5 resulted positive to TGF-bRII. Table 1.
Discussion
The possibility of targeting TGF-b signaling in HCC offers a
novel and appealing opportunity, because this pathway is
implicated in the worsening of the underlying chronic liver disease
and the onset of tumor progression [10,23]. In this study, we show
that LY2157299, currently being investigated in a clinical trial
phase II (NCT01246986, http://clinicaltrials.gov), acts like
LY2109761. We also found several differences between the small
molecule inhibitors and the monoclonal antibody targeting TGF-
bRII: 1) LY2157299 displays similar functionalities and biochem-
ical activities to those of LY2109761; 2) LY2157299 blocks
migration and tumor growth in vitro independently of the
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expression levels of TGF-bRs, whereas D10 does not; 3)
LY2157299 inhibits Smad-2 phosphorylation for a longer time
than D10, and pSmad-2 is a key mediator of TGF-b1-triggered
motility; 4) in patients with HCC, TGF-bRII is expressed in 33%
of the cases.
The effectiveness of LY2157299 and LY2109761 in inhibiting
HCC cell migration, and pSMAD2, E-cadherin, VEGF and
CTGF dephosphorylation, imply that both molecules share similar
activity profiles [13,20]. This study is the first report demonstrating
the effectiveness of LY2157299 on HCC cells in vitro, providing a
scientific rationale for using this drug in clinical trials. Also, it
presents direct comparisons between the two small molecule
inhibitors.
Recently, it has been reported that D10, a neutralizing antibody
directed against TGF-bRII, blocks breast cancer growth and
spread in animal models via inhibition of Smad-2 phosphorylation
[21]. Consistently with this report, in our experimental conditions
D10 also showed a de-phosphorylating activity on pSMAD2 at
short term incubation (30 minutes), but not after a longer time (24
hours), thus explaining its lack of activity on migration measured at
similar times.
Interestingly, in vitro TGF-b1 rearranges the way that HepG2
cells grow in nodule-like structures, transforming them into larger
cellular structures with a consequent down-regulation of E-
cadherin expression at cell-cell contact. Also in this case,
LY2157299 blocks TGF-b1 effects whereas D10 does not. Because
of these in vitro changes of HCC nodules, radiographic responses
using a modified RECIST [24] may be carefully evaluated and
perhaps offer a way to translate this observation into clinical
studies with LY2157299.
Finally, another important point is the expression of TGF-bRII.
This may help to select patients for treatment with D10. Of 30
patients, we detected the expression of this receptor on tumor
parenchyma in one third of the patients. If HCC patients for D10
therapy should be selected based on the expression of TGF-bRII,
then a larger study would need to be conducted to confirm that a
third of patients express the receptor. In the same group of
patients, 69% showed positive staining for p-Smad2, suggesting
activation of the pathway. These observations also confirm our
in vitro data that activation of TGF-b signaling occurs even if
TGF-bRII is apparently not expressed. Our data suggest that the
positive staining for p-Smad2 could represent a biomarker for
selecting patients more likely to benefit from anti-TGF-b therapy,
but further studies are needed to expand and confirm this
observation in a larger cohort of patients. At present, these data
represent an interesting observation and a preliminary report.
On the other hand it has been reported that TGF-b reduced
PLC/PRF/5 cell proliferation in vitro and that a low expression
of TGF-bRII in HCC tissues was correlated with a more
aggressive disease [11]. This is not entirely surprising considering
the well known double-sword effect of TGF-b. Also, the sensitivity
of the method should be taken into consideration and the fact that,
as we demonstrate in this study, the activation of the signaling can
occur following phosphorylation of Smad-2/3 also in the case of
low or no expression of TGF-bRII.
Furthermore, it is important to note that the receptor expression
on tumor cells is only one aspect in the patients selection
approach. The microenvironment and the immune cell expression
for this receptor need to be taken into consideration when limiting
the selection to tumor tissue expression alone.
In conclusion, we demonstrate that LY2157299 is effective on
HCC cells in vitro, providing the first evidence to support its use in
currently ongoing clinical trials.
Supporting Information
Figure S1 Effect of LY2157299 and D10 on proliferation
and apoptosis of HCC cell lines. (A) HepG2 and HLE cells
were incubated with LY2109761 (10 mM) or LY2157299 (10 mM)
or D10 (25 ng/mL) or IgG1 isotype as negative control (25 ng/
mL) and cell proliferation assay was performed on day 6. No effect
was observed in the presence of LY2109761 or LY2157299 or
D10 compared with control (IgG1 isotype). (B) HepG2 and HLE
cells were incubated with LY2109761 (10 mM) or LY2157299
(10 mM) or D10 (25 ng/mL) or IgG1 isotype as negative control
(25 ng/mL) and after 4 days of treatment, TUNEL assay was
performed. No apoptotic effect was observed in the presence of
LY2109761 or LY2157299 or D10 compared with control (IgG
isotype). DNAse-treated HLE cells were used as positive control.
(C) HepG2 and HLE cells were pre-incubated with an IgG1
isotype for 48 h and then stimulated or not with TGF-b1 (5 ng/
mL) for 30 min. Western blot analysis was then performed in the
presence or absence of IgG1 isotype or TGF-b1 through collagen
I. IgG1 isotype did not affect Smad-2 phosphorylation.
(TIF)
Figure S2 Silencing of SMAD3 does not affect HCC
migration. (A) SMAD3-knocked-down HepG2 and HLE cells
were pre-incubated with TGF-b1 for 48 hours and then allowed to
migrate through Collagen-I for 16 hours. (B) Western blot analysis
showing silencing of SMAD3 protein in HepG2 and HLE. b-actin
was used as loading control. **P,0.01, ***P,0.001.
(TIF)
Figure S3 MMP-2 is a downstream effector of SMAD2.
MMP-2 mRNA was upregulated in HepG2 cells following TGF-
b1 treatment. However, in SMAD2 siRNA cells, treatment with
TGF-b1 failed to increase MMP-2 mRNA levels (left panel).
SMAD2 silencing was detected by western blotting analysis (right
panel). ***P,0.001.
(TIF)
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